Evaluation of the efficacy and safety of Opicapone combined with levodopa

Opicapone (trade name: Ongentys) is a new peripherally selective catechol-O-methyltransferase (COMT) inhibitor. It is mainly used to treat the "on-off" fluctuation symptoms of Parkinson's disease (PD) patients. It increases the availability of dopamine in the central nervous system by inhibiting peripheral dopamine degradation and extending the half-life of levodopa. Used in conjunction with levodopa, it can increase the time patients are "on" during the day and improve motor control.

Multiple clinical studies have shown that the combined use of opicapone and levodopa can significantly improve the motor symptoms ofPD patients. Randomized controlled trials have shown that once-daily opicapone increases effective "on" time by approximately 1–2 hours while reducing "off" time and motor fluctuations compared with levodopa alone. Long-term follow-up shows that this combination therapy can maintain the efficacy and significantly improve patients' quality of life and ability to perform daily activities.

Opicapone was generally well tolerated. Common adverse reactions include Mild to moderate constipation, insomnia, blood pressure fluctuations and occasional nausea. The incidence of serious adverse events was low. When used in combination with levodopa, attention should be paid to dose adjustment to prevent hyperkinesis (dyskinesia) caused by excessive dopamine. Regular monitoring of blood pressure, heart rate and liver function can reduce potential risks, and patients should report any unusual symptoms.

Opicapone combined with levodopa provides a new treatment option for PD patients, especially for patients who experience "on-off" fluctuations after long-term levodopa treatment. Clinically, the dose should be adjusted individually based on the patient's symptoms and tolerance. Combined use can significantly improve motor control and quality of life. Overall, this combination therapy shows a good balance in efficacy and safety, providing a reliable solution for precise management of Parkinson's disease.

Reference link:https://www.drugs.com